Phase II trials for tirzepatide and survodutide, a GLP-1/glucagon receptor co-agonist, have also shown positive outcomes in people living with MASH and obesity, demonstrating reduction of inflammation without worsening of fibrosis (4, 69). This evidence concerns the gene GCG and obesity disorder.